Didier Decaudin

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 92 publications

Development of a rapid ex vivo tumor platform for drug response prediction in lung cancer.

Development of a rapid ex vivo tumor platform for drug response prediction in lung cancer.

Journal: NPJ precision oncology

Published: February 23, 2026

Selective, controlled release of ruthenium-based therapeutic agents: a targeted weapon against ovarian cancer

Selective, controlled release of ruthenium-based therapeutic agents: a targeted weapon against ovarian cancer

Journal: Medecine sciences : M/S

Published: November 19, 2025

A comprehensive analysis of humanized mouse models for the study of cancer immunotherapies.

A comprehensive analysis of humanized mouse models for the study of cancer immunotherapies.

Journal: Frontiers in immunology

Published: October 22, 2025

Publisher Correction: Targeting GRPR for sex hormone-dependent cancer after loss of E-cadherin.

Publisher Correction: Targeting GRPR for sex hormone-dependent cancer after loss of E-cadherin.

Journal: Nature

Published: July 14, 2025

Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer Patients.

Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer Patients.

Journal: Cancers

Published: July 09, 2024

PPP3CB overexpression mediates EGFR TKI resistance in lung tumors via calcineurin/MEK/ERK signaling.

PPP3CB overexpression mediates EGFR TKI resistance in lung tumors via calcineurin/MEK/ERK signaling.

Journal: Life science alliance

Published: June 06, 2024

A translational study for biomarker identification of PEP-010, a pro-apoptotic peptide restoring apoptosis in cancer models.

A translational study for biomarker identification of PEP-010, a pro-apoptotic peptide restoring apoptosis in cancer models.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: March 18, 2024

Cellular origin and clonal evolution of human dedifferentiated liposarcoma.

Cellular origin and clonal evolution of human dedifferentiated liposarcoma.

Journal: Nature communications

Published: December 13, 2023

Targeting GRPR for sex hormone-dependent cancer after loss of E-cadherin.

Targeting GRPR for sex hormone-dependent cancer after loss of E-cadherin.

Journal: Nature

Published: October 09, 2023

Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study.

Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study.

Journal: Current oncology (Toronto, Ont.)

Published: August 14, 2023

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma.

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma.

Journal: Cancers

Published: March 03, 2023

Corrigendum to "Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma" [Eur J Cancer 126 (2020) 93-103].

Corrigendum to "Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma" [Eur J Cancer 126 (2020) 93-103].

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 03, 2023

Showing 1-12 of 92

Last Updated: 09/26/2026